GH.18 Form # 10710 R:12.13

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form GROWTH HORMONE CRITERIA (INCLUDING SEROSTIM)

www.mainecarepdl.org Phone: 1-888-445-0497 Fax: 1-888-879-6938 Member ID #: | | | | | | | | Patient Name: DOB: (NOT MEDICARE NUMBER) Patient Address:___ Provider DEA: | | | | | | Provider NPI: | | | | | | | | | Provider Name: Phone:_____ Fax: Provider Address: Rx Address: _Rx phone:____ Pharmacy Name: Provider must fill all information above. It must be legible, correct and complete or form will be returned. NPI: _____ NABP: _____ NDC: _____ NDC: _____ (Pharmacy use only): *Genotropin & Norditropin preferred but require a clinical PA to establish diagnosis and medical necessity. **Davs Supply** Dosage Instructions Drug Name Strength **Ouantity** (34 retail / 90 mail order) Refills 1 2 3 4 5 Medical Necessity Documentation: **Growth Failure in Adults: Growth Failure in Children:** Adult with idiopathic GHD and ALL of the following □ Severe IGF-1 Deficiency if: 1. Child presentation (Iplex approvals based only on this criteria) 2. On continuous therapy since child 1. Height SD<=3.0 3. Has clinical indication to continue GH 2. Basal IGF-I SD<=3.0 3. Normal GH levels □ AIDS wasting Growth retardation in children with CRF prior to renal transplant Involuntary weight loss > 10% of pre-illness wt or BMI < 201. HT <3% AND AND either of 2. Growth velocity <10%1. Chronic diarrhea or \Box (XO) Turner Syndrome Discontinue GH if: 2. Chronic weakness and documented fever (30 days) in absence of concurrent illness or other explaination 1. Increase in growth velocity is not > 2 cm/year after 1 year Adult with GHD secondary to destructive pituitary lesion or 2. If BA > 14 yrs female, 16 yrs male in peri-pituitary or secondary to cranial radiation therapy or 3. HT > 3% for normal adult HT has not been achieved surgery or when all of the following are met: □ Children with Russel-Silver or Noonan Syndromes a. Patient receiving full supplement of other deficient □ Severe short stature hormones AND 1. HT < 3% or >2 SD below 50% AND b. Patient has clinical features of somatotropin deficiency 2. Growth velocity <10% over 1 year AND 3. Lack of response to standard GH stim. Tests; < 10ng documented by i. Severely decreased QOL using AGHDA for insulin/L-dopa/arginine/clonidine/glucagons questionnaire or ii. Bone density of <1sd by WHO Omnitrope (8) iii. Decreased exercise tolerance and adverse Tev-Tropin (8) cardiac risk profile Humatrope (8) iv. Cardiac decompensation Increlex (8) Saizen (8) Other:

Pursuant to the MaineCare Benefits Manual, Chapter I, Section 1.16, The Department regards adequate clinical records as essential for the delivery of quality care, such comprehensive records are key documents for post payment review. Your authorization certifies that the above request is medically necessary, meets the MaineCare criteria for prior authorization, does not exceed the medical needs of the member and is supported in your medical records.

Provider Signature: